
CORRECTION

In the ACADEMIC HIGHLIGHTS “Challenges and Solutions in Developing New Medications for Schizophrenia” (*J Clin Psychiatry* 2010;71[10]:1391–1399), all K_i values in the section “New Antipsychotics and Investigational Agents” should be pK_i values. Table 1 should be corrected as follows: the pK_i of iloperidone is 0.3 nM for α_1 and the pK_i of asenapine is 1.3 nM for D_2 , 0.07 nM for 5-HT_{2A}, 2.7 nM for 5-HT_{1A}, 0.11 nM for 5-HT₇, 1.2 nM for both α_1 and α_2 , 1.0 nM for H_1 , and >5,000 nM for M_1 . Additionally, in the “Muscarinic (M_1) Effects” section on page 1396, asenapine should be deleted from the list of agents with potent affinity for the M_1 receptor. In the “Newer Antipsychotics: Asenapine” section, the third sentence should read: “It is generally well tolerated, with somnolence the most common side effect due to its high affinity for H_1 receptors; however, despite its H_1 affinity, little weight gain has been observed (average of only 2 lb in year-long studies).”

The online table and text have been corrected.